What drives success for specialty pharmaceuticals?

Nature Reviews Drug Discovery

Volumn 7, Issue 7, 2008, Pages 563-567

  Gudiksen, Mark ^a   Fleming, Edd ^a   Furstenthal, Laura ^a   Ma, Philip ^a  

^a MCKINSEY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; AMIFOSTINE; ARSENIC TRIOXIDE; ASPARAGINASE MACROGOL; ATAZANAVIR; CALFACTANT; CARMUSTINE; CETRORELIX; CIDOFOVIR; CYTARABINE; DENILEUKIN DIFTITOX; DONEPEZIL; DRUG; GEMCITABINE; IMATINIB; IRINOTECAN; LAMIVUDINE PLUS ZIDOVUDINE; LARONIDASE; LEPIRUDIN; LETROZOLE; MIDODRINE; MONOCLONAL ANTIBODY; PILOCARPINE; PROSTAGLANDIN E2; RECOMBINANT PROTEIN; RITUXIMAB; SPECIALTY DRUG; TAMOXIFEN; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZIPRASIDONE;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ARTICLE; BIOTECHNOLOGY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTER SYNDROME; MOTIVATION; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROFIT;

COMMERCE; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 46449092247     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2594     Document Type: Article

References (0)